The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light
Submit your access request to explore how it can streamlines access to critical cannabis insights
"*" indicates required fields